Emerging data suggest Retatrutide , a dual agonist targeting both GLP-1 and GIP , could provide a promising advancement for body loss . Initial human trials have shown substantial losses in visceral https://getretatrutideaustralia.com/blog/retatrutide-results-side-effects-cost